Concept Design, Development and Preliminary Physical and Chemical Characterization of Tamoxifen-Guided-Mesoporous Silica Nanoparticles.
breast cancer
functionalized nanostructures
mesoporous silica nanoparticles
poly-ʟ-histidine
surface reactivity
tamoxifen
targeting vector
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
04 Jan 2021
04 Jan 2021
Historique:
received:
27
10
2020
revised:
14
12
2020
accepted:
16
12
2020
entrez:
7
1
2021
pubmed:
8
1
2021
medline:
10
4
2021
Statut:
epublish
Résumé
Conventional chemotherapies used for breast cancer (BC) treatment are non-selective, attacking both healthy and cancerous cells. Therefore, new technologies that enhance drug efficacy and ameliorate the off-target toxic effects exhibited by currently used anticancer drugs are urgently needed. Here we report the design and synthesis of novel mesoporous silica nanoparticles (MSNs) equipped with the hormonal drug tamoxifen (TAM) to facilitate guidance towards estrogen receptors (ERs) which are upregulated in breast tumours. TAM is linked to the MSNs using a poly-ʟ-histidine (PLH) polymer as a pH-sensitive gatekeeper, to ensure efficient delivery of encapsulated materials within the pores. XRD, HR-TEM, DLS, SEM, FT-IR and BET techniques were used to confirm the successful fabrication of MSNs. The MSNs have a high surface area (>1000 m
Identifiants
pubmed: 33406699
pii: molecules26010219
doi: 10.3390/molecules26010219
pmc: PMC7795496
pii:
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Drug Carriers
0
Tamoxifen
094ZI81Y45
Silicon Dioxide
7631-86-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Chem Soc Rev. 2017 Jun 21;46(12):3830-3852
pubmed: 28516983
Colloids Surf B Biointerfaces. 2013 Oct 1;110:138-47
pubmed: 23711784
Biomed Res Int. 2013;2013:960821
pubmed: 23865076
Biomater Sci. 2020 Mar 17;8(6):1759-1770
pubmed: 32010909
JAMA. 2013 Jul 10;310(2):218
pubmed: 23839767
Molecules. 2020 Mar 05;25(5):
pubmed: 32151063
Acta Biomater. 2017 Nov;63:150-162
pubmed: 28873341
BMJ. 1991 Feb 2;302(6771):272
pubmed: 1998793
ACS Nano. 2011 Feb 22;5(2):1366-75
pubmed: 21294526
Nanomedicine (Lond). 2017 Jun;12(11):1261-1279
pubmed: 28520529
J Med Chem. 2017 Aug 10;60(15):6693-6703
pubmed: 28699738
Bioorg Med Chem Lett. 2016 Oct 15;26(20):4879-4883
pubmed: 27662800
Bioconjug Chem. 2009 Dec;20(12):2247-53
pubmed: 19919059
Front Chem. 2019 Jun 17;7:332
pubmed: 31263688
ACS Appl Mater Interfaces. 2015 Jul 29;7(29):15777-89
pubmed: 26133753
J Org Chem. 1997 Oct 17;62(21):7512-7515
pubmed: 11671879
Chemistry. 2020 Dec 9;26(69):16318-16327
pubmed: 32735063
Nanomaterials (Basel). 2017 Jul 22;7(7):
pubmed: 28737672
Toxicol Lett. 2017 Aug 15;278:66-83
pubmed: 28689762
PLoS One. 2014 Sep 30;9(9):e108586
pubmed: 25268937
Biomed Pharmacother. 2014 May;68(4):429-38
pubmed: 24721327
Pharmaceutics. 2020 Jun 08;12(6):
pubmed: 32521684
Int J Nanomedicine. 2016 Oct 31;11:5645-5669
pubmed: 27920520
Br J Pharmacol. 2009 May;157(2):166-78
pubmed: 19459843
Int J Cancer. 2004 Dec 20;112(6):1056-64
pubmed: 15386350
Pharmaceutics. 2018 Aug 06;10(3):
pubmed: 30082647
Nanomaterials (Basel). 2020 Jun 30;10(7):
pubmed: 32630076
ACS Nano. 2016 Sep 27;10(9):8325-45
pubmed: 27419663
J Clin Invest. 2011 Oct;121(10):3797-803
pubmed: 21965336
J Exp Clin Cancer Res. 2017 Feb 6;36(1):24
pubmed: 28166836
Expert Opin Ther Pat. 2013 Oct;23(10):1247-71
pubmed: 23713677
Lancet. 2017 Jun 17;389(10087):2350
pubmed: 28635596
Future Oncol. 2014 Nov;10(14):2293-301
pubmed: 25471040
ACS Nano. 2015 Nov 24;9(11):11023-33
pubmed: 26456489
Angew Chem Int Ed Engl. 2020 Dec 21;59(52):23862-23869
pubmed: 32894638
Biomaterials. 2012 Dec;33(36):9239-45
pubmed: 23026709
P T. 2017 Dec;42(12):742-755
pubmed: 29234213
Small. 2009 Jan;5(1):57-62
pubmed: 19051185
Nanomedicine (Lond). 2012 Jan;7(1):111-20
pubmed: 22191780
Int J Cancer. 2000 Mar 20;89(2):111-7
pubmed: 10754487
Molecules. 2020 Aug 21;25(17):
pubmed: 32825791